The Assign Group to Standardize with Oracle Apps
Oracle reports that The Assign Group, a CRO based in Austria, has selected Oracle Health Sciences apps to streamline clinical data and clinical trial management across its network of European and South American affiliates.
Oracle Clinical, Oracle Remote Data Capture, Oracle Adverse Event Reporting System, and Oracle Thesaurus Management System will serve as the foundation of the Group's new data management infrastructure, and Oracle’s Siebel Clinical Trial Management System will serve as its centralized database for managing clinical trial processes.
Factors behind the decision included the CRO's desire for an off-the-shelf solution that would allow them to focus on business rather than IT systems, according to a company press release.
“Health sciences organizations like The Assign Group are increasingly looking to IT solutions to help streamline clinical data management and improve efficiency throughout the clinical trial process,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
Pfizer Reports Strong Phase III Results for Hympavzi in Hemophilia Patients with Inhibitors
June 26th 2025The Phase III BASIS trial found that once-weekly subcutaneous Hympavzi reduced treated bleed rates by 93% in patients with hemophilia A or B with inhibitors, offering a promising new prophylactic option for a population with limited therapeutic choices.
